Editorial for “Incremental Prognostic Value of Cardiac MRI ‐Based Right‐to‐Left Ventricular Blood Pool T2 Ratio in Patients With Dilated Cardiomyopathy”

Dilated cardiomyopathy (DCM) is characterized by left ventricular enlargement and systolic dysfunction in the absence of significant coronary artery disease or abnormal loading conditions. Despite advances in management, there is still substantial mortality in affected individuals, principally driven by progressive heart failure (HF) and sudden cardiac death (SCD). The recognition of individuals at highest risk remains a central clinical challenge. To this end, current clinical strategies—from advanced imaging to genetic testing—focus almost exclusively on the primary organ of failure: the heart itself. Cardiac MRI, for instance, provides several means of this cardiac-centric assessment: left ventricular ejection fraction (LVEF), and late gadolinium enhancement (LGE), strain analysis and mapping techniques [1–3]. While the prognostic power of these markers is undeniable, they predominantly reflect the intrinsic state of the heart itself. A more complete risk assessment, however, may be achieved by also considering the systemic consequences of the disease. This highlights a critical need for novel biomarkers that look beyond the myocardium to capture the body's systemic reaction to the failing heart, thereby adding a new and potentially crucial dimension to risk stratification. In this issue of the Journal of Magnetic Resonance Imaging